Evidence map›Paper›PMID 40800090›Full record

ArticleTranslational andrology and urology2025

Ji Feng, Bin Zheng, Jichen Wang, Qingjiang Xu, Qing Ouyang, Huaikang Li, Tongyu Jia, Yaohui Wang, Tianwei Cai, Yi Feng and 3 more

Abstract read
In one paragraph

Article in Translational andrology and urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Ji Feng *Medical School of Chinese PLA, Beijing, China.
Bin Zheng *Medical School of Chinese PLA, Beijing, China.
Jichen Wang *Medical School of Chinese PLA, Beijing, China.
Qingjiang XuMedical School of Chinese PLA, Beijing, China.
Qing OuyangBeijing Mentougou District Hospital, Beijing, China.
Huaikang LiDepartment of Urology, The Third Medical Centre, Chinese PLA General Hospital, Beijing, China.
Tongyu JiaMedical School of Chinese PLA, Beijing, China.
Yaohui WangDepartment of Urology, The Third Medical Centre, Chinese PLA General Hospital, Beijing, China.
Tianwei CaiMedical School of Chinese PLA, Beijing, China.
Yi FengMedical School of Chinese PLA, Beijing, China.
Xu ZhangDepartment of Urology, The Third Medical Centre, Chinese PLA General Hospital, Beijing, China.
Xiubin LiDepartment of Urology, The Third Medical Centre, Chinese PLA General Hospital, Beijing, China.
Xin MaDepartment of Urology, The Third Medical Centre, Chinese PLA General Hospital, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Clear cell renal cell carcinoma (ccRCC) represents the predominant form of kidney cancer. The Ras homology (Rho) GTPases family plays essential roles in several tumors. However, few studies have reported the function and clinical value of the Rho GTPases family in ccRCC. Our study aimed to systematically investigate the expression profiles, functional roles, and clinical significance of Rho GTPases in ccRCC, with the goal of identifying potential biomarkers and novel therapeutic targets to improve the treatment outcomes and survival rates of this aggressive kidney cancer. Methods: The expression level of Ras homolog family member J ( Results: Our study identified Conclusions: Taken together, our findings provide novel insights into the role of

Indexed as

clear cell renal cell carcinoma (ccRCC)drugsnuclear factor kappa B (NF-κB)Ras homolog family member J (RhoJ)tumor necrosis factor (TNF)

Identifiers

PMID40800090
PMCPMC12336740

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.